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Abstract
Background: Tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND) have unique, individual
patterns that pose significant challenges for diagnosis, psycho-education, and intervention planning. A recent study
suggested that it may be feasible to use TAND Checklist data and data-driven methods to generate natural TAND
clusters. However, the study had a small sample size and data from only two countries. Here, we investigated the
replicability of identifying natural TAND clusters from a larger and more diverse sample from the TOSCA study.
Methods: As part of the TOSCA international TSC registry study, this embedded research project collected TAND
Checklist data from individuals with TSC. Correlation coefficients were calculated for TAND variables to generate a
correlation matrix. Hierarchical cluster and factor analysis methods were used for data reduction and identification of
natural TAND clusters.
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Results: A total of 85 individuals with TSC (female:male, 40:45) from 7 countries were enrolled. Cluster analysis grouped
the TAND variables into 6 clusters: a scholastic cluster (reading, writing, spelling, mathematics, visuo-spatial difficulties,
disorientation), a hyperactive/impulsive cluster (hyperactivity, impulsivity, self-injurious behavior), a mood/anxiety cluster
(anxiety, depressed mood, sleep difficulties, shyness), a neuropsychological cluster (attention/concentration difficulties,
memory, attention, dual/multi-tasking, executive skills deficits), a dysregulated behavior cluster (mood swings,
aggressive outbursts, temper tantrums), and an autism spectrum disorder (ASD)-like cluster (delayed language, poor
eye contact, repetitive behaviors, unusual use of language, inflexibility, difficulties associated with eating). The natural
clusters mapped reasonably well onto the six-factor solution generated. Comparison between cluster and factor
solutions from this study and the earlier feasibility study showed significant similarity, particularly in cluster solutions.
Conclusions: Results from this TOSCA research project in an independent international data set showed that the
combination of cluster analysis and factor analysis may be able to identify clinically meaningful natural TAND clusters.
Findings were remarkably similar to those identified in the earlier feasibility study, supporting the potential robustness
of these natural TAND clusters. Further steps should include examination of larger samples, investigation of internal
consistency, and evaluation of the robustness of the proposed natural clusters.
Keywords: ASD, Cluster analysis, Factor analysis, Natural TAND clusters, TAND, Tuberous sclerosis complex, TOSCA,
Registry, Neuropsychiatric
Background
Tuberous sclerosis complex (TSC) is a complex multi-
system genetic disorder with a vast and variable age-
related presentation of physical and neuropsychiatric
manifestations [1–3]. It is associated with a substantial
economic and psychosocial burden on the affected indi-
viduals and their families [1, 4–7].
In spite of the high rates and burden of neuropsychiatric
manifestations in individuals with TSC, a 2010 study from
the UK reported that only 18% of all families had ever re-
ceived any of the recommended evaluations or treatments
for the range of neuropsychiatric manifestations [8]. These
findings suggested a large assessment and treatment gap in
TSC. In order to reduce this gap, the Neuropsychiatry Panel
of the International Consensus Guidelines Group coined the
term TAND (TSC-associated neuropsychiatric disorders) in
2012 [9] and presented a standardized nomenclature to de-
scribe the range of neuropsychiatric manifestations observed
in TSC across six levels—behavioral, psychiatric, intellectual,
academic, neuropsychological, and psychosocial. The Neuro-
psychiatry Panel also recommended that all individuals with
TSC should be screened for TAND on an annual basis [9].
In order to support screening for TAND, a TAND Checklist
was developed through a participatory research strategy and
pilot validated [10, 11].
Individuals with TSC have unique and highly variable
TAND profiles. This uniqueness and multi-dimensionality
of TAND often lead to ‘treatment paralysis’ where most
clinical teams feel overwhelmed by the complexity of the
neuropsychiatric presentations of their patients with TSC,
thus posing a significant challenge to clinicians for diagno-
sis, psycho-education, and intervention planning [12, 13].
To reduce the assessment gap and treatment paralysis
seen in the TSC community, the possibility of identifying
“natural clusters” of the TAND phenomena was hypothe-
sized by Leclezio and de Vries [12]. They proposed that, if
data-driven strategies could identify a manageable number
of clusters, this could reduce the assessment and treat-
ment gap by providing clinical next steps [13]. The re-
searchers proposed this to be an essential first step
towards personalisation of clinical concerns, guiding the
generation of evidence-based treatments for TAND and
adding precision to training and fundamental neurosci-
ence research [13].
In a feasibility study, Leclezio and colleagues explored
methods that may identify natural clusters [14]. Findings
identified WARD’s cluster analysis and exploratory fac-
tor analysis as potential methods and produced six nat-
ural clusters with good face validity. However, the study
had a small sample size (n = 56) and included patients
from only two countries (South Africa and Australia).
Given the highly heterogeneous nature of TAND mani-
festations, it was therefore not clear to what extent the
six identified clusters would be replicable.
In this study, we set out to examine a new sample of
individuals with TSC across ages and abilities from seven
countries to determine whether data reduction methods
would be able to replicate and extend the findings from
the feasibility study performed by Leclezio et al. [14].
Methods
Design
The detailed methodology of the overall TOSCA clinical
study has been published previously [15]. In brief,
TOSCA was a non-interventional, multicenter, natural
history registry of individuals with TSC. The study was
designed with a “core” section and six research projects,
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each focusing on a specific area of TSC—subependymal
giant cell astrocytoma, renal angiomyolipoma, genetics,
epilepsy, quality of life, and TAND. Here, we present
data on the research project focusing on TAND.
Subjects and procedures for this research project
All centers participating in the TOSCA clinical study
were invited to participate in the TAND research pro-
ject. Centers from seven countries opted to participate.
All TOSCA participants from these countries were
therefore invited to participate in this study. Upon
provision of a dedicated informed consent for the TAND
research project, the TAND Checklist was administered
to individuals with TSC or their caregivers by a study
physician [10]. The TAND Checklist follows the neuro-
psychiatric levels of investigation outlined previously [10,
11] and consists of the following 12 sections: (1) basic
developmental milestones; (2) current level of function-
ing; (3) behavioral difficulties; (4) psychiatric disorders
diagnosed; (5) intellectual ability; (6) academic difficul-
ties; (7) neuropsychological deficits; (8) psychosocial
functioning; (9) parent, caregiver, or self-rating of the
impact of TAND; (10) prioritization list; (11) additional
concerns; and (12) health care professional rating of the
impact of TAND. The questions require simple yes or
no responses in most sections.
Data analysis
In contrast to “hypothesis-testing” statistical approaches
where data are analyzed in relation to an a priori predic-
tion, unsupervised learning or data-driven methods
searches for previously undetected patterns or groupings
in a dataset without any a priori rules, predictions, or la-
bels to data. In this study, we used cluster analysis and
factor analysis, two unsupervised learning/data-driven
statistical methods, to help understand the complex
TAND data. The objectives of cluster and factor analysis
methods are, however, different. Cluster analysis aims to
group observations (e.g., a sample of subjects or vari-
ables) into distinct groups in a way that objects in that
group are more similar to each other than to those in
other clusters or groups. Many different methods are
used for cluster analysis. In the proof-of-principle study
by Leclezio et al. [14], a wide range of cluster analysis
methods were explored and the WARD method was
identified as the most suitable method for the TAND
Checklist data used. WARD is a hierarchical cluster ana-
lysis method. The method starts with each object as a
separate cluster. At each sequential step, the two closest
clusters are merged. The WARD method bases the
closeness of clusters on within cluster variance. The se-
quential merging is typically visualized in a dendrogram
(or hierarchical tree).
In contrast to the intuitive stepwise WARD clustering
algorithm, factor analysis is based on fitting a model to
the data. Factor analysis is typically used as a data reduc-
tion method to reduce a larger set of variables into a much
smaller number of factors. The model assumes a few un-
observable “latent (or underlying) factors” in the data. Fac-
tor analysis uses the correlations between variables (e.g.,
TAND checklist items) to identify latent factors represent-
ing a group of highly correlated variables. (A group of
highly correlated variables will tend to vary jointly, thus
reducing the within group variance). Factor analysis data
are typically visualized as correlation matrices showing the
factor loadings of items included in each factor. Factor
score plots represent a different visualization method and
show how factor scores contribute to each factor. In the
Leclezio et al. study [14], a range of exploratory factor ana-
lysis methods were used for extraction and rotation of
data to find a factor solution that best matched the cluster
analysis method. Ultimately both methods (cluster and
factor analysis) group similar items, but follow very differ-
ent approaches. In general, where the two methods con-
verge on the same findings, this allows one to place
increased confidence in those findings.
In order to replicate the proof-of-concept work by Lecle-
zio et al. [14], we included exactly the same variables for
analysis. The following sections of the TAND Checklist
were included: Section 3, behavioral challenges (19 ques-
tions/variables); Section 6, academic skills (four variables);
and Section 7, neuropsychological skills (six variables). In
the original study, variables were included that were (a) de-
scriptive of observed phenomena, e.g., the behavioral, scho-
lastic or neuropsychological levels, and (b) that could have
been answered without access to specialist care (e.g., no
need for diagnosis or formal testing). Given that all the vari-
ables had binary (yes/no), a scoring coefficient was used to
compute a correlation matrix for the variables of interest.
In case of missing values, variables were omitted pairwise in
correlation computations. Hierarchical cluster analysis was
used to identify natural clusters and to generate a clustering
tree (dendrogram) visually representing the merging of
TAND variables and suggesting a suitable number of clus-
ters. Factor analysis was performed for data reduction based
on correlation between the variables. The number of factors
in the model was matched to the number of natural clus-
ters identified. Cluster and factor solutions were compared
to examine overlap between the two data reduction
methods. In the absence of access to data to perform a dir-
ect statistical comparison, a narrative comparison was made
of the cluster and factor solutions between this study and
the feasibility study [14].
Results
Eighty-five individuals (31 adults and 54 children) from
7 countries were enrolled in this research project. The
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demographic characteristics of the participants are
shown in Table 1. Median age at consent was 14 years
(mean, 17.8 years; range, 2–72 years).
Cluster analysis and exploratory factor analysis
Hierarchical clustering identified six natural clusters of
TAND variables as the most parsimonious solution. A den-
drogram detailing these six natural clusters is shown in Fig.
1. The first cluster included difficulties with reading, writ-
ing, spelling, mathematics, visuo-spatial tasks, restlessness,
and disorientation, suggesting a natural “scholastic” cluster.
The second cluster included mood swings, aggressive out-
bursts, and temper tantrums, suggesting a natural “dysregu-
lated behavior” cluster. The third cluster included
difficulties in attention/concentration, deficits in memory,
neuropsychological attention deficits, dual/multi-tasking,
and executive skills. These characteristics suggested a nat-
ural “neuropsychological” cluster. The fourth cluster in-
cluded anxiety, depressed mood, sleep difficulties, and
extreme shyness, suggesting a natural “mood/anxiety” clus-
ter. The fifth cluster included self-injurious behavior, hyper-
activity, and impulsivity, suggesting a natural “hyperactive/
impulsive” cluster. The sixth cluster included delayed lan-
guage, poor eye contact, repetitive behaviors, unusual use
of language, rigidity or inflexibility, and difficulties associ-
ated with eating. These characteristics suggested a natural
“autism spectrum disorder (ASD)-like” cluster. The ex-
ploratory factor analysis findings are shown in Figs. 2 and 3.
Comparison of cluster analysis and factor analysis
The similarities and differences between cluster analysis
and exploratory factor analysis are shown in Fig. 4. The
six factors mapped reasonably well onto the natural clus-
ters identified as linked to scholastic skills, ASD, dysreg-
ulated behavior, neuropsychological deficits, hyperactive/
impulsive behaviors, and mood/anxiety. With the excep-
tion of poor eye contact, there was a 100% overlap be-
tween the “ASD-like” natural TAND cluster and the
ASD-related factor solution (delayed language, repetitive
behaviors, unusual use of language, rigidity or inflexibil-
ity, and difficulties associated with eating). In the hyper-
active/impulsive natural TAND cluster, factor analysis
included one additional characteristic (restlessness), but
the other items were identical. In the dysregulated be-
havior natural TAND cluster, factor analysis included
one additional characteristic (extreme shyness), and
grouped mood swings with neuropsychological attention
deficits and behavioral attention deficits. Aggressive out-
bursts and temper tantrums were both present in the
dysregulated behavior cluster and factor. With regard to
the mood/anxiety natural TAND cluster, factor analysis
had grouped extreme shyness with other items in the
dysregulated behavior cluster. Other mood/anxiety items
were the same in the cluster and factor solutions. In the
scholastic natural TAND cluster, factor analysis included
three neuropsychological variables (dual/multi-tasking,
memory, and executive skills), but the other items were
identical. A separate “neuropsychological attentional fac-
tor” with high cross-loading onto the other neuro-
psychological variables and the neuropsychological
cluster was identified.
Narrative comparison of findings between the feasibility
study (Leclezio et al. 2018) and the present study
Cluster solutions
The majority of items from the TAND Checklist were
grouped similarly between the two studies. Both the
feasibility study and this study showed six natural clus-
ters, with identical findings for the dysregulated behavior
and mood/anxiety clusters between the studies (Table
2). In the ASD-like cluster, five variables (language, un-
usual language, repetitive behavior, poor eye contact,
and eating difficulties) were identical between the stud-
ies. However, this study also included peer difficulties
and inflexibility with the ASD-like cluster. This grouping
has good face validity in relation to the clinical charac-
teristics of ASD. In terms of the scholastic cluster, all
core scholastic items (difficulties with reading, writing,
Table 1 Demographic characteristics
Overall participants (N = 85)
Sex, n (%)
Male 40 (47.1)
Female 45 (52.9)
Age strata (years), n (%)
≤ 2 1 (1.2)
> 2 to ≤ 5 11 (12.9)
> 5 to ≤ 9 16 (18.8)
> 9 to ≤14 17 (20.0)
> 14 to < 18 9 (10.6)
≥ 18 to ≤ 40 22 (25.9)
> 40 9 (10.6)
Age at consent, years
Mean (SD) 17.8 (14.57)
Median (range) 14 (2–72)
Country of residence, n (%)
Belgium 18 (21.2)
France 33 (38.8)
Germany 7 (8.2)
Spain 7 (8.2)
UK 4 (4.7)
Japan 15 (17.6)
Turkey 1 (1.2)
SD standard deviation, UK United Kingdom
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spelling, mathematical problems) were grouped together
in the feasibility study and in this study. However, two
items that appeared more neuropsychological in con-
struct (disorientation and visuo-spatial deficits) were also
grouped in the scholastic cluster in the present study. In
the hyperactive/impulsive cluster, overactivity, and im-
pulsivity were grouped together in the feasibility study
and in this study, but restlessness (grouped with hyper-
active/impulsive behaviors in the feasibility study) was
clustered in the scholastic cluster in this study. In both
studies, attention deficits (behavioral level and neuro-
psychological attention deficits) clustered separately
from the overactive/impulsive items.
Factor solutions
We observed less consistency in factor solutions between
the two studies. In the ASD-like factor of this study, al-
most all the variables were identical to those in the feasi-
bility study, except that our factor analysis excluded self-
injury, disorientation, poor eye contact, and difficulty in
visuo-spatial tasks, and included inflexibility in the factor
(Table 2). In the overactive/impulsive factor, three vari-
ables (overactive, impulsive, and restlessness) were identi-
cal, but inflexibility and self-injury grouped with different
factors. Both dysregulated behavior and mood/anxiety
factors had almost identical variables, apart from anxiety
and extreme shyness that switched factors between the
studies. The mood/anxiety factor in the present study ex-
cluded memory. In this study, we observed a combined
“scholastic and neuropsychological” factor and a new “at-
tentional” factor that included behavioral attention defi-
cits, neuropsychological attention deficits, and mood
swings.
Discussion
Identification of natural TAND clusters through data-
driven methods has been proposed as a potential solution
for the “treatment paralysis” seen in TSC, given the highly
variable and apparently unique nature of TAND profiles
in individuals. In a proof-of-principle study, Leclezio,
Gardner, and de Vries showed the feasibility of using data
reduction methods in TAND and identified six putative
natural clusters [14]. However, the sample size of the
Leclezio study was very small, and individuals were re-
cruited from only two countries. Given these limitations
and the highly heterogeneous nature of TSC, we set out to
replicate the feasibility findings in a larger sample of 85
individuals, including children, from seven countries. We
observed six natural TAND clusters (scholastic, ASD-like,
dysregulated behavior, neuropsychological, overactive/
Fig. 1 Dendrogram of natural TAND clusters. Hierarchical cluster analysis using the WARD method produced six natural TAND clusters
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impulsive, and mood/anxiety). These were remarkably
similar to those identified by Leclezio et al. in the feasibil-
ity study [14], but had more mixed results in factor solu-
tions, thus providing partial replication of the finding of
potential natural TAND clusters. However, while some
items were clearly differently grouped using data-driven
strategies between the feasibility study and this study,
many similarities were seen, suggesting that, in spite of
the vast heterogeneity of TAND, there may be robust nat-
ural clusters of TAND manifestations that should be ex-
plored further in larger-scale studies [16–18].
Currently, many families and clinical teams are un-
aware of which of all the possible TAND manifesta-
tions to look out for and how to provide appropriate
evidence-based, next-step interventions. If a limited
number of natural clusters are confirmed, clinical
monitoring, and next steps of psycho-education and
intervention for six or so clusters of difficulties would
be much more feasible. For instance, it may be possible
then to develop modular training based on specific clus-
ters, such as specific programs for dysregulated behavior
in TSC or for mood/anxiety cluster features.
Fig. 2 Exploratory factor analysis results of a six-factor solution to identify the latent constructs underlying the TAND variables. The figure shows the
rotated factor pattern using the Varimax method. Coefficients in blue represent the largest coefficient values for each variable across all 6 factors. All
other coefficients with values > 0.5 are shown in yellow
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Fig. 3 Visualization of the factor score graph showing factor scores of individual TAND variables in relation to the six-factor solution derived from
exploratory factor analysis. The closer a factor score is to + 1 the stronger the influence of the factor is on that variable. Solid blue dots represent
the largest coefficient values for each variable across all 6 factors and solid yellow dots represent all other coefficients with values > 0.5. Blue
circles represent coefficients with values < 0.5
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It was of interest that some of the natural clustering
was in groups that make intuitive diagnostic sense from
clinical criteria, such as the ASD-like cluster. TSC is
known to be one of the medical conditions most
strongly associated with ASD [6]. However, it was also
interesting to observe that the hyperactive/impulsive fea-
tures did not cluster with the inattention features, in
contrast with the typical clinical grouping of manifesta-
tions associated with attention deficit/hyperactivity dis-
order (ADHD). In both the feasibility and this study,
behavioral attention deficits were more likely to cluster
with neuropsychological attention-executive skill deficits.
All these proposals will require further evaluation in
larger-scale studies.
For the purposes of this early-phase replication study,
we wanted to see if, first, we were able to identify robust
methodologies and whether they would replicate in an
independent sample, and second, whether natural clus-
ters could be identified even in the absence of age and
intellectual ability data. The association between age and
intellectual ability on TAND clusters, however, raises
interesting conceptual and empirical questions. It is
likely that TAND cluster profiles may emerge or change
over time. For instance, the scholastic cluster is likely
not to be relevant in the first few years of life. Similarly,
intellectual ability may be a very strong marker of the
likelihood of TAND clusters. These important questions
will require larger-scale and longitudinal datasets.
In comparison to the feasibility study [14] where only
English-speaking participants were used, we deliberately
aimed to include a more culturally and linguistically di-
verse sample to examine the robustness of the putative
TAND clusters identified. The sample therefore included
French, Dutch, English, German, Spanish, Turkish, and
Japanese participants. The TAND Checklist has been
translated and authorized in 17 languages to date, and
where available, those language versions were used.
Larger-scale studies may allow for a comparison of
TAND cluster profiles in different cultural and language
groups. However, to date, there are no clinical sugges-
tions that TAND manifestations have differential cul-
tural expression.
Fig. 4 Comparison of cluster analysis and exploratory factor analysis to show the overlap between cluster and factor solutions. Dotted lines
indicate natural TAND clusters; solid lines show factor analysis solutions
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Table 2 Comparison of clusters and factors between the feasibility study (Leclezio et al. 2018) and this study (the replication study)
Clusters and factors Variables
Both feasibility and replication
studies
Replication study
(current study)
Feasibility study
(Leclezio et al. 2018)
TAND clusters
1. Mood/anxiety Anxiety (Banx)
Depressed mood (Bdep)
Extreme shyness (Bshy)
Sleep difficulties (Bsleep)
- -
2. Dysregulated behavior Mood swings (Bmood)
Aggressive outbursts (Baggr)
Temper tantrums (Btemp)
- -
3. ASD-like Absent or delayed language
(Blang)
Repeating words or phrases
(BU.lan)
Poor eye contact (Beye)
Repetitive behaviors (Brep)
Difficulties with eating (Beat)
Peer difficulties (Bp.diff)
Rigidity/inflexibility (Bflex)
Self-injury (Bs.inj)
Visuo-spatial difficulties (NPSv.spat)
4. Hyperactive/impulsive Overactivity (Bo.act)
Impulsivity (Bimpul)
Self-injury (Bs.inj) Rigidity/inflexibility (Bflex)
Restlessness (Brestl)
5. Neuropsychological Difficulty paying attention
(Ba.diff)
Memory difficulties (NPSmem)
Attention difficulties (NPSatt)
Dual-tasking difficulties
(NPSd.task)
Executive difficulties (NPSexe)
- Visuo-spatial difficulties (NPSdisor)
Peer difficulties (Bp.diff)
6. Scholastic Reading difficulties (SCread)
Writing difficulties (SCwrit)
Spelling difficulties (SCspel)
Mathematics difficulties
(SCmath)
Restlessness (Brestl)
Visuo-spatial difficulties (NPSv.spat)
Disorientation (NPSdisor)
-
TAND factors
1. Scholastic and
Neuropsychological
Dueal-task difficulties
(NPSd.task)
Executive difficulties (NPSexe)
Mathematics difficulties
(SCmath)
Reading difficulties (SCread)
Writing difficulties (SCwrit)
Spelling difficulties (SCspel)
Visuo-spatial difficulties (NPSv.spat)
Memory difficulties (NPSmem)
Disorientation (NPSdisor)
Poor eye contact (Beye)
Attention difficulties (Ba.diff)
Neuropsychological attention difficulties
(NPSatt)
2. ASD-like Absent or delayed language
(Blang)
Repeating words or phrases
(BU.lan)
Peer difficulties (Bp.diff)
Repetitive behaviors (Brep)
Eating difficulties (Beat)
Rigidity/inflexibility (Bflex) Visuo-spatial difficulties (NPSv.spat)
Disorientation (NPSdisor)
Self-injury (Bs.inj)
Poor eye contact (Beye)
3. Hyperactive/impulsive Restlessness (Brestl)
Overactivity (Bo.act)
Impulsivity (Bimpul)
Self-injury (Bs.inj) Rigidity/inflexibility (Bflex)
4. Dysregulated behavior Aggressive outbursts (Baggr)
Temper tantrums (Btemp)
Extreme shyness (Bshy) Anxiety (Banx)
Mood swings (Bmood)
5. Mood/anxiety Depressed mood (Bdep)
Sleep difficulties (Bsleep)
Anxiety (Banx) Memory difficulties (NPSmem)
Extreme shyness (Bshy)
6. Attentional -NA- Neuropsychological attention difficulties
(NPSatt)
Attention difficulties (Ba.diff)
Mood swings (Bmood)
-NA-
ASD autism spectrum disorder
The columns show all TAND Checklist items included in the study and the abbreviation for each variable in parenthesis e.g. Anxiety (Banx)
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Limitations and next steps
There are several potential limitations to this study. We
acknowledge that, even though this study sample was
larger and more diverse than that of the feasibility study,
the sample size was still small, even for a rare disease.
We were aiming to recruit from a large natural history
study (TOSCA study) and were therefore hopeful to in-
clude a much larger sample for this study. However,
given that it was embedded in an industry-funded obser-
vational trial, a formal procedure for opting in at a coun-
try level was required. Where countries opted in, all
participants at centers were included. While we there-
fore acknowledge an “administrative” bias in recruit-
ment, we have no reason to suspect a clinical
ascertainment bias, given that all subjects from partici-
pating centers had a TAND Checklist completed.
Interestingly, there is no consensus in the literature
about the required sample size for cluster analysis, and a
number of small-scale studies such as ours have identi-
fied meaningful natural clusters [19]. Some authors have
suggested a minimum sample size of n = 100, while
others emphasized the importance of an optimal vari-
able/subject ratio with a 1:10 ratio (1 variable to 10 sub-
jects) as most stringent suggestion [20]. Given the
differences observed between the feasibility and replica-
tion data sets, we propose that it would be important to
proceed to examination of larger-scale samples, ideally
in excess of the 1/10 (variable/subject) ratio. Secondly,
apart from cluster and factor analysis, it would be im-
portant to evaluate the internal consistency of putative
natural clusters and to examine the robustness of these
clusters using bootstrapping methodologies. These extra
steps will extend the investigation of the psychometric
properties and robustness of the putative natural TAND
clusters. We also acknowledge that the natural clusters
were generated using only the TAND Checklist data.
There may therefore be other natural clusters that could
be identified using different kinds of fine-grain data.
However, the purpose of the TAND Checklist was to
provide a simple and easy-to-use tool for clinical prac-
tice. For this reason, we set out to examine the potential
of the TAND Checklist data to generate natural TAND
Clusters, given that such a strategy has a far greater po-
tential for larger-scale implementation.
Conclusion
In spite of the highly heterogeneous nature of TAND
manifestations, the data-driven strategies used here in
search of natural TAND clusters were able to replicate
the findings from the feasibility study in a larger sample
of children and adults with the pen-and-paper TAND
Checklist data collected across seven countries. The
study not only identified several similarities between the
findings from the two data sets but also identified key
aspects and next steps that will require larger-scale data,
replication, and expansion. If these steps could replicate
and extend the natural TAND clusters suggested in
these preliminary studies, the natural TAND clusters
may have the potential to help develop novel approaches
to identification and treatment of TAND and may sug-
gest novel data-driven strategies to subgroup individuals
with TSC for clinical and research purposes.
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